Clin2
NCT07610135Worth exploringRecruiting

Psilocybin with or without pimavanserin pretreatment

Mood (Psychological Function)Well BeingMoodHealthy

Treatments studied

Part of Mental health clinical trials.

This trial tests whether taking pimavanserin before psilocybin changes the drug's effects in healthy volunteers who have never used psychedelics. It aims to understand how to make psychedelic therapy safer and more predictable.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
20 people
Ages
21 years to 65 years
Study type
Interventional

Who can take part

  • Aged 21 to 65 years old
  • Right-handed
  • No past use of psychedelic drugs like psilocybin, LSD, MDMA, or ketamine
  • No current or past psychiatric conditions (like depression, bipolar, or substance use disorder)
  • Not currently taking antidepressants, antipsychotics, or other neuropsychiatric medications
  • No first-degree relative with schizophrenia, bipolar I, or other psychotic disorders

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05301608Recruiting· Phase 1/Phase 2
Psilocybin study of brain activity and changing thoughts

This Phase 1/2 study tests psilocybin to see how it affects brain signals and the “content” of thoughts while you are monitored during the study. Because participants must be generally healthy and mentally stable, it may be an option if you meet those safety and medication rules and are comfortable having your brain activity measured.

Baltimore, Maryland
NCT07079852Not yet recruiting· Phase 1/Phase 2
Psilocybin and its effects on memory and brain function

This trial tests how psilocybin, a psychedelic substance, affects your thinking, memory, and brain activity. Researchers want to understand these effects in healthy adults who have used psychedelics before.

Austin, Texas
NCT06796361Recruiting· Phase 1
Psilocybin's effect on consciousness: serotonin receptor role

This study tests how psilocybin (the active ingredient in magic mushrooms) affects consciousness by blocking a specific serotonin receptor in the brain. It helps researchers understand why psilocybin causes altered states of mind.

Basel, Canton of Basel-City
NCT07565493Recruiting· Early Phase 1
Psilocybin with a serotonin blocker in healthy adults

This early-stage research study tests how psilocybin (a naturally occurring compound from certain mushrooms) works when combined with a medication that blocks a specific serotonin pathway in the brain. Researchers want to understand how these two substances interact in healthy volunteers to inform future psychiatric treatment studies.

Baltimore, Maryland
NCT07180108Enrolling by invitation· Phase 1
Psilocybin and music study for healthy volunteers

This study tests how music affects your experience with psilocybin, a psychedelic substance. It may help researchers understand how to create the best setting for psilocybin therapy.

Baltimore, Maryland
NCT06592833Recruiting· Phase 2
Psilocybin with or without pimavanserin for depression

This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.

New York, New York

Hear when a new Well-being trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.